Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"
08 September 2020 - 9:30PM
Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company
developing innovative gene therapies, today announced that the
company will provide a corporate overview and participate in 1:1
meetings at upcoming virtual investor and patient conferences in
September. Additionally, the company announced plans for their 1st
Parkinson’s Disease R&D Day with key opinion leaders.
Investor and Patient Conference Presentation
details:
Baird Global
Healthcare Conference |
Date: |
Wednesday, September 9, 2020 |
Time: |
9:40 AM ET |
|
|
2020 Virtual GM1
Family Meeting |
Date: |
Thursday, September 10, 2020 |
Time: |
6:45 PM ET |
Registration Link: |
https://curegm1.org/2020-gm1-family-meeting-san-francisco/ |
|
|
Cantor Fitzgerald
Virtual Global Healthcare Conference |
Date: |
Thursday, September 17, 2020 |
Time: |
1:20 PM ET |
Webcast link: |
https://www.webcaster4.com/Webcast/Page/2495/37417 |
|
|
20th Annual Biotech
in Europe Forum |
Date: |
Thursday, September 24, 2020 |
Time: |
9:00 AM ET |
Registration link: |
https://www.sachsforum.com/20bef-registration.html |
|
|
AXO-Lenti-PD
Parkinson’s Disease R&D Day |
Date: |
Friday, October 30, 2020 |
Moderator: |
Gavin Corcoran, MD, Chief R&D Officer, Axovant Gene
Therapies |
Additional details to be provided later in September. |
A live webcast of the presentations will be available in the
Events section of Axovant's website at www.axovant.com. A replay
will be available for approximately 30 days following the
conference.
About Axovant Gene
Therapies
Axovant Gene Therapies is a clinical-stage gene
therapy company focused on developing a pipeline of innovative
product candidates for debilitating neurodegenerative diseases. Our
current pipeline of gene therapy candidates target GM1
gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease
and Sandhoff disease), and Parkinson’s disease. Axovant is focused
on accelerating product candidates into and through clinical trials
with a team of experts in gene therapy development and through
external partnerships with leading gene therapy organizations. For
more information, visit www.axovant.com.
Contacts:
Media & Investors
Parag MeswaniAxovant Gene Therapies Ltd.(212)
547-2523media@axovant.cominvestors@axovant.com
Source: Axovant Gene Therapies
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From May 2024 to Jun 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Axovant Gene Therapies Ltd (NASDAQ): 0 recent articles
More News Articles